Sinco Pharmaceuticals Holdings Limited (SINCO PHARMA, 06833) has issued a notice convening its 2026 Annual General Meeting (AGM) for 10:00 a.m. on 15 May 2026 at Room E5-1805, New Century Global Center, Chengdu, Sichuan.
Key items on the AGM agenda:
1. FY25 Results Adoption • Shareholders will vote on receiving and adopting the audited consolidated financial statements for the year ended 31 December 2025 together with directors’ and independent auditor’s reports.
2. Board Composition and Remuneration • Re-election of three independent non-executive directors: Mr Wang Qing, Mr Bai Zhizhong and Mr Lau Ying Kit. • Authorisation for the board to determine directors’ remuneration.
3. Auditor Re-appointment • Proposal to re-appoint Rongcheng (Hong Kong) CPA Limited (formerly CL Partners CPA Limited) as external auditor until the conclusion of the next AGM, with the board empowered to set audit fees for FY26.
4. Dividend Proposal • A final dividend of HK0.167 cents per share, totalling approximately HK$3.40 million for FY25, is recommended. • Subject to approval, the dividend is scheduled for payment on or around 4 June 2026. • Share transfer books will close from 21 May to 26 May 2026; shareholders must lodge transfers by 4:30 p.m. on 20 May 2026 to qualify.
5. General Mandates • Share Issue Mandate: Authority for the board to allot and issue up to 20% of the company’s issued share capital during the defined “Relevant Period.” • Share Repurchase Mandate: Permission to repurchase up to 10% of issued shares on the Hong Kong Stock Exchange within the same period. • Extension Mandate: The share issue limit may be increased by the number of shares repurchased under the buy-back mandate.
Shareholders intending to attend and vote must be registered by 4:30 p.m. on 11 May 2026; the register of members will be closed from 12 May to 15 May 2026 for AGM purposes.
The notice was authorised by Vice Chairman and Executive Director Mr Huang Zhijian and dated 20 April 2026.
Comments